Nuvalent, Inc. (NASDAQ:NUVL) director Matthew Shair has sold a total of $2,566,478 worth of company stock, according to the latest SEC filings. The transactions occurred on April 8, 2024, and were executed within a price range of $67.89 to $69.64 per share.
The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information. This plan had been adopted by Shair on December 21, 2023.
Shair's transactions included multiple sales of Nuvalent's Class A Common Stock at varying prices. The first batch of 11,022 shares was sold at a weighted average price of $67.89. The second sale included 25,478 shares at an average price of $68.63, and the third and final sale involved 1,000 shares at an average price of $69.64. The sales were made in multiple transactions at prices that ranged from as low as $67.16 to as high as $70.19.
Following these transactions, Shair still holds a significant amount of Nuvalent stock. It's noted that an additional 238,522 shares are held indirectly by the Matthew D. Shair 2021 Irrevocable Family Trust, over which he retains voting and dispositive power.
Nuvalent, Inc., based in Cambridge, Massachusetts, is a pharmaceutical company that specializes in the development of targeted therapies for patients with cancer. The company's shares are traded on the NASDAQ stock exchange under the ticker symbol NUVL.
Investors often monitor insider transactions as they may provide insights into the company's performance and insider perspectives on the value of the stock. The Form 4 filing with the SEC provides transparency on such transactions, ensuring that the market stays informed about the trading activities of company insiders.
InvestingPro Insights
Nuvalent, Inc. (NASDAQ:NUVL) has caught the attention of investors not only through insider trading activities but also through its financial metrics and market performance. According to real-time data from InvestingPro, Nuvalent holds a market capitalization of approximately $4.29 billion. Despite the recent insider sales, the company's stock has experienced a significant return of 165.89% over the past year, showcasing a strong performance in the market.
However, the company's financial health shows some concerns. With an adjusted P/E ratio of -31.7 as of the last twelve months ending Q4 2023 and an operating income of -$149.49 million, Nuvalent's profitability is under scrutiny. This is further underlined by an InvestingPro Tip indicating that analysts do not anticipate the company to be profitable this year. Another tip reveals that Nuvalent's stock has taken a substantial hit over the last week, with a price total return of -7.51%, which may be a point of interest for potential investors considering the recent insider sales.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available that delve into aspects such as the company's cash position versus debt, earnings revisions, and gross profit margins. To access these insights and more, visit InvestingPro and consider using the coupon code PRONEWS24 for an extra 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are 14 additional InvestingPro Tips that could provide valuable context and inform investment decisions regarding Nuvalent, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.